Etodolac
- PDF / 165,448 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 72 Downloads / 177 Views
1
★S
First report of depressed-type colorectal cancer: case report A 61-year-old man developed depressed-type early invasive colorectal cancer during treatment with etodolac for knee joint pain. The man presented with multiple colorectal polyps and underwent resection of all polyps > 5mm in size, while polyps ≤ 5mm were left in his colon and rectum. During an outpatient follow-up, he started receiving etodolac [Hypen] 200mg twice daily and, 6 months later, a follow-up colonoscopy showed six polyps, which had decreased in size, and a depressed-type lesion (5mm in size) in his distal transverse colon. A chromoendoscopy with magnification showed a type III-type pit pattern in his depressed area. Based on his endoscopic findings, his lesion was estimated to be a cancer, which was limited within his mucosal layer or slightly invading his submucosal layer. The man underwent an endoscopic mucosal resection and his lesion was completely resected. A histopathological analysis showed well-differentiated adenocarcinoma slightly invading the submucosal layer and without adenomatous components. Follow-up colonoscopies showed no recurrence. Kaihara T, et al. Depressed-type early invasive colon cancer in a patient treated with cyclooxygenase-2 inhibitor. Digestive Diseases and Sciences 51: 885-888, No. 801041692 5, May 2006 - Japan
» Editorial comment: A search of AdisBase and Medline did not reveal any previous case reports of depressed-type colorectal cancer associated with etodolac. The WHO Adverse Drug Reactions database contained no reports of colon carcinoma or rectal carcinoma associated with etodolac.
0114-9954/10/1112-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 29 Jul 2006 No. 1112
